Trial reportEuropean journal of nuclear medicine and molecular imaging2004
A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.
Trial report in European journal of nuclear medicine and molecular imaging, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.European journal of nuclear medicine and molecular imaging · 2013Guideline
- Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma.Radiation oncology (London, England) · 2012Trial
- Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy.European journal of nuclear medicine and molecular imaging · 2011Trial
- Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?European journal of nuclear medicine and molecular imaging · 2006Trial
- Comparison of radiolabeled somatostatin analogs (DOTATATE, DOTANOC, and DOTATOC) in somatostatin receptor (SSTR) imaging for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a narrative literature review.Annals of nuclear medicine · 2025Review
- 68Ga-DOTATOC PET/CT in the Localization of Pituitary Tumors in Cushing's Disease.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Altered biodistribution of [European journal of nuclear medicine and molecular imaging · 2024Article
- Comparison ofHeliyon · 2024Article
- Single-time-point dosimetry using model selection and nonlinear mixed-effects modelling: a proof of concept.EJNMMI physics · 2023Article
- Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.Theranostics · 2022Review
- From the Magic Bullet to Theragnostics: Certitudes and Hypotheses, Trying to Optimize the Somatostatin Model.Cancers · 2021Review
- Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy.Molecules (Basel, Switzerland) · 2020Review
- Development of NovelBiomolecules · 2020Article
- Correlation of dose with toxicity and tumour response toEuropean journal of nuclear medicine and molecular imaging · 2018Review
- Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy.Chemistry (Weinheim an der Bergstrasse, Germany) · 2018Article
- Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review.Theranostics · 2017Review
- IMPROVED PLANAR KIDNEY ACTIVITY CONCENTRATION ESTIMATE BY THE POSTERIOR VIEW METHOD IN 177LU-DOTATATE TREATMENTS.Radiation protection dosimetry · 2016Article
- (68)Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging.European journal of nuclear medicine and molecular imaging · 2016Article
- Quantitative SPECT/CT Imaging of (177)Lu with In Vivo Validation in Patients Undergoing Peptide Receptor Radionuclide Therapy.Molecular imaging and biology · 2015Article
- PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma.European journal of nuclear medicine and molecular imaging · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
[Yttrium-90-DOTA-Tyr(3)]-octreotide (DOTATOC) and [(177)Lu-DOTA-Tyr(3)-Thr(8)]-octreotide (DOTATATE) are used for peptide receptor-mediated radionuclide therapy (PRMRT) in neuroendocrine tumours. No human data comparing these two compounds are available so far. We used (111)In as a surrogate for (90)Y and (177)Lu and examined whether one of the (111)In-labelled peptides had a more favourable biodistribution in patients with neuroendocrine tumours. Special emphasis was given to kidney uptake and tumour-to-kidney ratio since kidney toxicity is usually the dose-limiting factor. Five patients with metastatic neuroendocrine tumours were injected with 222 MBq (111)In-DOTATOC and (111)In-DOTATATE within 2 weeks. Up to 48 h after injection, whole-body scans were performed and blood and urine samples were collected. The mean absorbed dose was calculated for tumours, kidney, liver, spleen and bone marrow. In all cases (111)In-DOTATATE showed a higher uptake (%IA) in kidney and liver. The amount of (111)In-DOTATOC excreted into the urine was significantly higher than for (111)In-DOTATATE. The mean absorbed dose to the red marrow was nearly identical. (111)In-DOTATOC showed a higher tumour-to-kidney absorbed dose ratio in seven of nine evaluated tumours. The variability of the tumour-to-kidney ratio was high and the significance level in favour of (111)In-DOTATOC was P=0.065. In five patients the pharmacokinetics of (111)In-DOTATOC and (111)In-DOTATATE was found to be comparable. The two peptides appear to be nearly equivalent for PRMRT in neuroendocrine tumours, with minor advantages for (111)In/(90)Y-DOTATOC; on this basis, we shall continue to use (90)Y-DOTATOC for PRMRT in patients with metastatic neuroendocrine tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.